BioCentury

7:00 AM GMT, Aug 1, 2011
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Regulatory

Velcade bortezomib regulatory update

The U.K.'s NICE issued final guidance recommending the use of thalidomide from Celgene Corp. (NASDAQ:CELG, Summit, N.J.) and Velcade bortezomib from

Read the full 213 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.